HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical OTC Drugs

Prepaid Cards Could Help OTC Switches Gain Against Rx Competitors

This article was originally published in The Tan Sheet

  • News

Executive Summary

Medagate Corp.’s payment technology that simplifies insurance reimbursement for OTCs could help level the playing field with competing prescription products.

You may also be interested in...



Asthma Treatment OTC Switches Would Face Tough Barriers

Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.

The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization

The next generation of consumer health products, including Rx-to-OTC switch opportunities, may work in concert with cutting-edge diagnostic tools and elements of personalized medicine, says Andrew Fish.

Zyrtec OTC Launch Does Not Deliver Knockout To Rx Remedies – Report

Fewer consumers than expected have switched from Rx products to OTC Zyrtec in part because managed care organizations are not discouraging use of prescription allergy medications, according to research by Nielsen and Wolters Kluwer Health
Table

View full table

Related Content

Pink Sheet Pink Sheet

Topics

Tags:
BioPharmaceutical OTC Drugs
UsernamePublicRestriction

Register

RS134062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By